Westwood Holdings Group Inc. Acquires 239 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Westwood Holdings Group Inc. increased its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,993 shares of the medical equipment provider’s stock after purchasing an additional 239 shares during the period. Westwood Holdings Group Inc.’s holdings in Zimmer Biomet were worth $325,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of ZBH. OLD Point Trust & Financial Services N A bought a new stake in Zimmer Biomet in the fourth quarter worth $26,000. Ables Iannone Moore & Associates Inc. bought a new stake in Zimmer Biomet in the fourth quarter worth $30,000. Crewe Advisors LLC bought a new stake in Zimmer Biomet in the first quarter worth $31,000. Family Firm Inc. bought a new stake in Zimmer Biomet in the second quarter worth $33,000. Finally, J.Safra Asset Management Corp boosted its holdings in Zimmer Biomet by 712.1% during the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 235 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 0.1 %

Shares of ZBH opened at $106.42 on Monday. The stock has a market cap of $21.89 billion, a price-to-earnings ratio of 23.03, a P/E/G ratio of 1.96 and a beta of 1.02. The company has a quick ratio of 0.63, a current ratio of 1.29 and a debt-to-equity ratio of 0.31. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $133.90. The company has a 50-day moving average price of $109.83 and a two-hundred day moving average price of $115.38.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, August 7th. The medical equipment provider reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.02. Zimmer Biomet had a net margin of 13.25% and a return on equity of 12.86%. The company had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. During the same quarter in the previous year, the company posted $1.82 earnings per share. Zimmer Biomet’s quarterly revenue was up 3.9% compared to the same quarter last year. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.02 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend is Monday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 20.78%.

Wall Street Analyst Weigh In

ZBH has been the topic of several research analyst reports. Robert W. Baird lowered their price target on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Raymond James lowered their price target on Zimmer Biomet from $138.00 to $128.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. TD Cowen lowered their price target on Zimmer Biomet from $143.00 to $119.00 and set a “hold” rating on the stock in a research report on Friday, September 6th. Royal Bank of Canada lowered their price target on Zimmer Biomet from $140.00 to $130.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Finally, Piper Sandler downgraded Zimmer Biomet from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $140.00 to $115.00 in a research report on Monday, July 1st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $125.17.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.